ClinicalTrials.gg

Program

Immunoglobulins

Also written as “IgPro10”, “TAK-771” and “Immunoglobulins Intravenous (Human)”.

Its studies are mostly in Primary Immunodeficiency Diseases · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Agammaglobulinemia · Scleroderma, Diffuse · Purpura, Thrombocytopenic, Idiopathic, led by 4 companies.

Furthest: phase 4, since Jul 7, 201119 company-led studies, 2 open or runningNext primary completion: Dec 20, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSL111 open or runningphase 4since Jul 7, 2011Sep 12, 2005Dec 20, 2029phase 4 · NCT03684018
Takeda60 open or runningphase 3since Sep 11, 2015Sep 11, 2015none ahead
GC Biopharma10 open or runningphase 3since Feb 19, 2018Feb 19, 2018none ahead
Kedrion11 open or runningphase 3since Dec 16, 2024Dec 16, 2024Dec 20, 2027phase 3 · NCT06752356

Also a collaborator on its studies: takeda-development-center-americas-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 4 studies since Sep 12, 2005.

  1. Sep 8, 2010Phase 3 study in Primary Immunodeficiency DiseasesCSL · NCT01199705 · 25 enrolled · Japan
  2. Jul 7, 2011Phase 4 study in Purpura, Thrombocytopenic, IdiopathicCSL · NCT01390649 · 57 enrolled · Bulgaria, Romania, Serbia
  3. Sep 11, 2015Takeda's first study: phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNew to TakedaTakeda · NCT02549170 · 138 enrolled · United States, Argentina, Brazil and more
  4. Mar 7, 2016Phase 4 study in Primary Immunodeficiency DiseasesCSL · NCT02711228 · 26 enrolled · Canada
  5. Feb 19, 2018GC Biopharma's first study: phase 3 study in Primary Immunodeficiency DiseasesNew to GC BiopharmaGC Biopharma · NCT03492710
  6. Sep 24, 2018Phase 4 study in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)CSL · NCT03684018 · 30 planned · United States
  7. Oct 14, 20192 phase 2 studies in Scleroderma, DiffuseCSL · NCT04138485, NCT04137224
  8. Apr 10, 2020Phase 3 study in Primary Immunodeficiency DiseasesTakeda · NCT04346108 · 17 enrolled · Japan
  9. Apr 11, 2021Phase 3 study in Primary Immunodeficiency DiseasesTakeda · NCT04842643 · 12 enrolled · Japan
  10. Oct 10, 2021Phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingTakeda · NCT05084053 · 26 enrolled · Japan
  11. Nov 24, 2021Phase 3 study in Primary Immunodeficiency DiseasesTakeda · NCT05150340 · 16 enrolled · Japan
  12. Aug 22, 2022Phase 3 study in Primary Immunodeficiency DiseasesTakeda · NCT05513586 · 15 enrolled · Japan
  13. Dec 16, 2024Kedrion's first study: phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNew to KedrionKedrion · NCT06752356 · 161 planned · United States
  14. Jul 15, 2025Phase 4 study in Primary Immunodeficiency DiseasesCSL · NCT07076446 · 8 enrolled · United States

Ahead

  1. Dec 20, 2027Primary completion: phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingKedrion · NCT06752356
  2. Dec 20, 2029Primary completion: phase 4 study in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)CSL · NCT03684018

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 19 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07076446Primary Immunodeficiency Diseases · United States4CompletedCSLJun 30, 20268
NCT06752356Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States3RecruitingKedrionDec 20, 2027161
NCT05513586Primary Immunodeficiency Diseases · Japan3CompletedTakedaOct 30, 202515
NCT05150340Primary Immunodeficiency Diseases · Japan3CompletedTakedaAug 28, 202316
NCT05084053Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Japan3CompletedTakedaOct 28, 202526
NCT04842643Primary Immunodeficiency Diseases · Japan3CompletedTakedaApr 25, 202412
NCT04346108Primary Immunodeficiency Diseases · Japan3CompletedTakedaDec 22, 202117
NCT04137224Scleroderma, Diffuse · Australia, Germany, Italy and more2CompletedCSLMay 17, 202227
NCT04138485Scleroderma, Diffuse · United States, Argentina, Australia and more2WithdrawnCSLSep 16, 20200
NCT03684018Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) · United States4RecruitingCSLDec 20, 202930
NCT03492710Primary Immunodeficiency Diseases3WithdrawnGC BiopharmaApr 30, 20190
NCT02711228Primary Immunodeficiency Diseases · Canada4CompletedCSLJan 30, 201826
NCT02549170Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Argentina, Brazil and more3CompletedTakedaFeb 23, 2022138
NCT01390649Purpura, Thrombocytopenic, Idiopathic · Bulgaria, Romania, Serbia4CompletedCSLSep 201457
NCT01199705Primary Immunodeficiency Diseases · Japan3CompletedCSLAug 201125
NCT00322556Agammaglobulinemia · United States3CompletedCSLApr 200855
NCT00168038Purpura, Thrombocytopenic, Idiopathic · Germany, Italy, Poland and more3CompletedCSL58
NCT00168025Agammaglobulinemia3CompletedCSL89
NCT00168012Agammaglobulinemia3CompletedCSL42

How it is read

Names in the registry

  • “IgPro10”, 4 entries
  • “TAK-771”, 3 entries
  • “Immunoglobulins Intravenous (Human)”, 3 entries
  • “Immunoglobulin”, 2 entries
  • “Immune globulin (human) 10% solution for intravenous administration”, 1 entry

Codes read as this program: IGPRO10.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.